Switching off a single enzyme in immune cells protected mice from obesity, type 2 diabetes, and fatty liver disease in a new study, offering a potential new treatment target for metabolic disorders.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The risk for type 2 diabetes is more than two times ...

Obstacles to preventing and treating obesity, including limited access to healthy foods, limited time to prepare meals and ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

Get a load of this — you may be obese after all! About 40% of US adults — more than 100 million Americans — are considered ...

Youth with obesity but without type 2 diabetes were 31% less likely to develop type 2 diabetes if they were prescribed a glucagon-like peptide 1 (GLP-1) receptor agonist medication instead of an older ...

© Copyright Agri-Pulse Communications, Inc. WASHINGTON, July 6 - Scientists at the National Institutes of Health have uncovered a pathway in mice that allows white ...

Please provide your email address to receive an email when new articles are posted on . Obesity therapy may raise risk for hypoglycemia and diabetic ketoacidosis in people with type 1 diabetes. A ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study. Blocking ...